Question · asked by 1 review

Summary of findings: pioglitazone monotherapy vs placebo: Non‐fatal myocardial infarction/stroke

It is very uncertain whether summary of findings: pioglitazone monotherapy changes non‐fatal myocardial infarction/stroke (N) compared with placebo (very low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Summary of findings: pioglitazone monotherapy vs placebo
Non‐fatal myocardial infarction/stroke (N) · people at increased risk for developing T2DM
It is very uncertain whether summary of findings: pioglitazone monotherapy changes non‐fatal myocardial infarction/stroke (N) compared with placebo (very low certainty).
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane Headline outcomes only
RR 1.97 [0.18, 21.65]3 studies · 789 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of…
2020 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.